Nonsurgical management of urinary incontinence in women: A clinical practice guideline from the American College of Physicians

Annals of Internal Medicine

Volumn 161, Issue 6, 2014, Pages 429-440

  Qaseem, Amir ^a   Dallas, Paul ^b   Forciea, Mary Ann ^c   Starkey, Melissa ^a   Denberg, Thomas D ^d   Shekelle, Paul ^e  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CARILION CLINIC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; DULOXETINE; ESTRIOL; ESTROGEN; FESOTERODINE; FLAVOXATE; MIRABEGRON; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLABEGRON; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADVERSE OUTCOME; BEHAVIOR THERAPY; BLADDER TRAINING; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; CONTINENCE; DISEASE SEVERITY; ELECTROMYOGRAM; ESTROGEN THERAPY; FEEDBACK SYSTEM; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SCHOOL; OUTCOME ASSESSMENT; PELVIC FLOOR MUSCLE TRAINING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; STRESS INCONTINENCE; TREATMENT DURATION; TREATMENT RESPONSE; URGE INCONTINENCE; URINE INCONTINENCE; VISUAL FEEDBACK; WEIGHT REDUCTION; ARTICLE; BLADDER; ELECTROMYOGRAPHY; FEMALE; KINESIOTHERAPY; METHODOLOGY; OBESITY; PELVIS FLOOR; PSYCHOPHYSIOLOGY;

BEHAVIOR THERAPY; BIOFEEDBACK, PSYCHOLOGY; ELECTROMYOGRAPHY; EXERCISE THERAPY; FEMALE; HUMANS; OBESITY; PELVIC FLOOR; QUALITY OF LIFE; URINARY BLADDER; URINARY INCONTINENCE; WEIGHT LOSS;

EID: 84907187441     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2410     Document Type: Review

References (163)

1. Carls C. The prevalence of stress urinary incontinence in high school and college-age female athletes in the midwest: implications for education and prevention. Urol Nurs. 2007; 27:21-4. [PMID: 17390923]
2. Kinchen KS, Lee J, Fireman B, Hunkeler E, Nehemiah JL, Curtice TG. The prevalence, burden, and treatment of urinary incontinence among women in a managed care plan. J Womens Health (Larchmt). 2007; 16:415-22. [PMID: 17439386]
3. Sampselle CM, Harlow SD, Skurnick J, Brubaker L, Bondarenko I. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol. 2002; 100:1230-8. [PMID: 12468167]
4. Griffiths AN, Makam A, Edwards GJ. Should we actively screen for urinary and anal incontinence in the general gynaecology outpatients setting?-a prospective observational study. J Obstet Gynaecol. 2006; 26:442-4. [PMID: 16846873]
5. Shamliyan T, Wyman J, Bliss DZ, Kane RL, Wilt TJ. Prevention of urinary and fecal incontinence in adults. Evid Rep Technol Assess (Full Rep). 2007:1-379. [PMID: 18457475]
6. Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health. 2006; 9:272-4. [PMID: 16903997]
7. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al; International Urogynecological Association. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29:4-20. [PMID: 19941278] doi:10.1002/nau.20798
8. Hay Smith J, Berghmans B, Burgio K, Dumoulin C, Hagen S, Moore K, et al. Committee 12: adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 4th International Consultation on Incontinence, Paris, July 5-8, 2008. Paris: Health Publications; 2009:1025-120.
9. U.S. Department of Health and Human Services; U.S. Food and Drug Administration; Center for Devices and Radiological Health. Draft Guidance for Industry and FDA Staff: Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence. Rockville, MD: U.S. Food and Drug Administration; 2008.
10. Yalcin I, Peng G, Viktrup L, Bump RC. Reductions in stress urinary incontinence episodes: what is clinically important for women? Neurourol Urodyn. 2010; 29:344-7. [PMID: 19475576] doi:10.1002/nau.20744
11. Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review no. 36. AHRQ publication no. 11(12)-EHC074-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Accessed at www.effectivehealthcare.ahrq.gov/ehc/products/169/834/urinary-incontinence-treatment-report-130909.pdf on 31 July 2014.
12. Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews. 1st ed. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
13. Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012; 156:861-74. [PMID: 22711079] doi: 10.7326/0003-4819-156-12-201206190-00436
14. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010; 153:194-9. [PMID: 20679562] doi: 10.7326/0003-4819-153-3-201008030-00010
15. Wenger NS, Roth CP, Shekelle PG, Young RT, Solomon DH, Kamberg CJ, et al. A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia. J Am Geriatr Soc. 2009; 57:547-55. [PMID: 19175441] doi:10.1111/j.1532-5415.2008.02128.x
16. Aksac B, Aki S, Karan A, Yalcin O, Isikoglu M, Eskiyurt N. Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence. Gynecol Obstet Invest. 2003; 56:23-7. [PMID: 12867764]
17. Bø K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ. 1999; 318:487-93. [PMID: 10024253]
18. Kim H, Yoshida H, Suzuki T. Exercise treatment to reduce the urine leakage in elderly community-dwelling Japanese women with stress, urge, and mixed urinary incontinence [Abstract]. Presented at 39th Annual Meeting of the International Continence Society, San Francisco, California, 29 September-3 October 2009. Abstract no. 772.
19. Burns PA, Pranikoff K, Nochajski T, Desotelle P, Harwood MK. Treatment of stress incontinence with pelvic floor exercises and biofeedback. J Am Geriatr Soc. 1990; 38:341-4. [PMID: 2179379]
20. Burns PA, Pranikoff K, Nochajski TH, Hadley EC, Levy KJ, Ory MG. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. J Gerontol. 1993; 48:M167-74. [PMID: 8315230]
21. Castro RA, Arruda RM, Zanetti MR, Santos PD, Sartori MG, Girão MJ. Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. Clinics (Sao Paulo). 2008; 63:465-72. [PMID: 18719756]
22. Hung HC, Hsiao SM, Chih SY, Lin HH, Tsauo JY. An alternative intervention for urinary incontinence: retraining diaphragmatic, deep abdominal and pelvic floor muscle coordinated function. Man Ther. 2010; 15:273-9. [PMID: 20185357] doi:10.1016/j.math.2010.01.008
23. Lagro-Janssen TL, Debruyne FM, Smits AJ, van Weel C. Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. Br J Gen Pract. 1991; 41:445-9. [PMID: 1807303]
24. Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002; 50:808-16. [PMID: 12028165]
25. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991; 265:609-13. [PMID: 1987410]
26. Subak LL, Quesenberry CP, Posner SF, Cattolica E, Soghikian K. The effect of behavioral therapy on urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2002; 100:72-8. [PMID: 12100806]
27. Williams KS, Assassa RP, Gillies CL, Abrams KR, Turner DA, Shaw C, et al; Leicestershire MRC Incontinence Study Team. A randomized controlled trial of the effectiveness of pelvic floor therapies for urodynamic stress and mixed incontinence. BJU Int. 2006; 98:1043-50. [PMID: 17034605]
28. Diokno AC, Sampselle CM, Herzog AR, Raghunathan TE, Hines S, Messer K, et al. Prevention of urinary incontinence by behavioral modification program: a randomized, controlled trial among older women in the community. J Urol. 2004; 171:1165-71. [PMID: 14767293]
29. Kumari S, Jain V, Mandal AK, Singh A. Behavioral therapy for urinary incontinence in India. Int J Gynaecol Obstet. 2008; 103:125-30. [PMID: 18755458] doi:10.1016/j.ijgo.2008.06.019
30. Lagro-Janssen AL, Debruyne FM, Smits AJ, van Weel C. The effects of treatment of urinary incontinence in general practice. Fam Pract. 1992; 9:284-9. [PMID: 1459383]
31. McFall SL, Yerkes AM, Cowan LD. Outcomes of a small group educational intervention for urinary incontinence: episodes of incontinence and other urinary symptoms. J Aging Health. 2000; 12:250-67. [PMID: 11010699]
32. O'Brien J, Austin M, Sethi P, O'Boyle P. Urinary incontinence: prevalence, need for treatment, and effectiveness of intervention by nurse. BMJ. 1991; 303: 1308-12. [PMID: 1747675]
33. Kim JI. Continence efficacy intervention program for community residing women with stress urinary incontinence in Japan. Public Health Nurs. 2001; 18: 64-72. [PMID: 11251875]
34. Moore KH, O'Sullivan RJ, Simons A, Prashar S, Anderson P, Louey M. Randomised controlled trial of nurse continence advisor therapy compared with standard urogynaecology regimen for conservative incontinence treatment: efficacy, costs and two year follow up. BJOG. 2003; 110:649-57. [PMID: 12842055]
35. Williams KS, Assassa RP, Cooper NJ, Turner DA, Shaw C, Abrams KR, et al; Leicestershire MRC Incontinence Study Team. Clinical and cost-effectiveness of a new nurse-led continence service: a randomised controlled trial. Br J Gen Pract. 2005; 55:696-703. [PMID: 16176737]
36. O'Brien J. Evaluating primary care interventions for incontinence. Nurs Stand. 1996; 10:40-3. [PMID: 8695463]
37. Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005; 174:190-5. [PMID: 15947625]
38. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al; PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009; 360:481-90. [PMID: 19179316] doi:10.1056/NEJMoa0806375
39. Holtedahl K, Verelst M, Schiefloe A. A population based, randomized, controlled trial of conservative treatment for urinary incontinence in women. Acta Obstet Gynecol Scand. 1998; 77:671-7. [PMID: 9688247]
40. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmeno-pausal women. Menopause. 2004; 11:49-56. [PMID: 14716182]
41. Rufford J, Hextall A, Cardozo L, Khullar V. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14:78-83. [PMID: 12851747]
42. Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton J, Wallace R, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol. 2005; 106:946-52. [PMID: 16260511]
43. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012; 285:397-403. [PMID: 21706345] doi:10.1007/s00404-011-1955-1
44. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int. 2004; 93:311-8. [PMID: 14764128]
45. Norton PA, Zinner NR, Yalcin I, Bump RC; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002; 187:40-8. [PMID: 12114886]
46. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. 2004; 104:511-9. [PMID: 15339761]
47. Cardozo L, Lange R, Voss S, Beardsworth A, Manning M, Viktrup L, et al. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence. Curr Med Res Opin. 2010; 26:253-61. [PMID: 19929591] doi:10.1185/03007990903438295
48. Lin AT, Sun MJ, Tai HL, Chuang YC, Huang ST, Wang N, et al. Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. BMC Urol. 2008; 8:2. [PMID: 18221532] doi:10.1186/1471-2490-8-2
49. Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC. Minimal clinically important differences in incontinence quality-of-life scores in stress urinary incontinence. Urology. 2006; 67:1304-8. [PMID: 16750246]
50. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003; 170:1259-63. [PMID: 14501737]
51. Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, et al; Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007; 100:337-45. [PMID: 17511767]
52. Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007; 23:2347-58. [PMID: 17706004]
53. Hill S, Khullar V, Wyndaele JJ, Lheritier K; Darifenacin Study Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2006; 17:239-47. [PMID: 15999217]
54. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005; 95:580-6. [PMID: 15705084]
55. Kaplan SA, Schneider T, Foote J, Guan Z. Superior efficacy of fesoterodine over tolterodine with rapid onset: a prospective, head-to-head, placebo-controlled trial [Abstract]. Presented at Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010. Abstract no. 67.
56. Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB). ClinicalTrials.gov NCT00444925. Accessed at http://clinicaltrials.gov/show/NCT00444925 31 July 2014.
57. Huang AJ, Hess R, Arya LA, Richter HE, Subak LL, Bradley CS, et al. Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. Am J Obstet Gynecol. 2012; 206:444.e1-11. [PMID: 22542122] doi:10.1016/j.ajog.2012.03.002
58. Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010; 75:62-8. [PMID: 19931895] doi:10.1016/j.urology.2009.09.018
59. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010; 105: 58-66. [PMID: 20132103] doi:10.1111/j.1464-410X.2009.09086.x
60. Fesoterodine Flexible Dose Study. ClinicalTrials.gov: NCT00536484. Accessed at http://clinicaltrials.gov/show/NCT00536484 on 31 July 2014.
61. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998; 280:1995-2000. [PMID: 9863850]
62. Goode PS. Behavioral and drug therapy for urinary incontinence. Urology. 2004; 63:58-64. [PMID: 15013654]
63. Lehtoranta K, Tainio H, Lukkari-Lax E, Hakonen T, Tammela TL. Phar-macokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol. 2002; 36:18-24. [PMID: 12002352]
64. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990; 66:479-85. [PMID: 2249115]
65. Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009; 181:1764-72. [PMID: 19233423] doi:10.1016/j.juro.2008.11.125
66. Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998; 81:801-10. [PMID: 9666761]
67. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol. 2004; 22: 251-6. [PMID: 15455256]
68. Homma Y, Paick JS, Lee JG, Kawabe K; Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an over-active bladder: a randomized, placebo-controlled trial. BJU Int. 2003; 92:741-7. [PMID: 14616458]
69. Johnson TM 2nd, Burgio KL, Redden DT, Wright KC, Goode PS. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc. 2005; 53:846-50. [PMID: 15877562]
70. Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiver-ine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999; 84:646-51. [PMID: 10510109]
71. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing. 1995; 24:287-91. [PMID: 7484484]
72. Thüroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propanthe-line versus placebo. J Urol. 1991; 145:813-6. [PMID: 2005707]
73. Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology. 2006; 68:999-1004. [PMID: 17113893]
74. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Mürtz G, et al. Efficacy and cardiac safety of propiverine in elderly patients-a double-blind, placebo-controlled clinical study. Eur Urol. 2000; 37:702-8. [PMID: 10828671]
75. Jünemann KP, Hessdörfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006; 77:334-9. [PMID: 17135784]
76. Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU Int. 2010; 105:1565-70. [PMID: 19912183] doi:10.1111/j.1464-410X.2009.09050.x
77. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2006; 17:512-9. [PMID: 16625311]
78. Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Curr Ther Res Clin Exp. 2009; 70:405-20. [PMID: 24692834] doi:10.1016/j.curtheres.2009.11.001
79. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2009; 73:14-8. [PMID: 18995887] doi:10.1016/j.urology.2008.08.485
80. Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int. 2006; 97:1256-61. [PMID: 16686722]
81. Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial. Int J Clin Pract. 2009; 63: 1702-14. [PMID: 19930331] doi:10.1111/j.1742-1241.2009.02209.x
82. Toglia MR, Serels SR, Laramée C, Karram MM, Nandy IM, Andoh M, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med. 2009; 121:151-8. [PMID: 19820284] doi:10.3810/pgm.2009.09.2062
83. Cardozo L, Amarenco G, Pushkar D, Mikulas J, Drogendijk T, Wright M, et al; SUNRISE Study Group. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013; 111:804-10. [PMID: 23294801] doi:10.1111/j.1464-410X.2012.11654.x
84. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 2003; 92:415-7. [PMID: 12930431]
85. Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19:1551-7. [PMID: 18685795] doi:10.1007/s00192-008-0688-6
86. Freeman R, Hill S, Millard R, Slack M, Sutherst J; Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol. 2003; 102:605-11. [PMID: 12962951]
87. Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin. 2008; 24:3513-21. [PMID: 19032133] doi:10.1185/03007990802537122
88. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002; 8:S608-15. [PMID: 12516955]
89. Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Curr Med Res Opin. 2009; 25:2159-65. [PMID: 19601704] doi:10.1185/03007990903103279
90. Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20:827-35. [PMID: 19495545] doi:10.1007/s00192-009-0857-2
91. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008; 71:449-54. [PMID: 18342185] doi:10.1016/j.urology.2007.11.008
92. Sand PK, Dmochowski RR, Zinner NR, Staskin DR, Appell RA. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20:1431-8. [PMID: 19727537] doi:10.1007/s00192-009-0969-8
93. Staskin D, Sand P, Zinner N, Dmochowski R; Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007; 178: 978-83. [PMID: 17632131]
94. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004; 171:2311-5. [PMID: 15126811]
95. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004; 5:423-6. [PMID: 15541209]
96. Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespeci-fied pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013; 67: 619-32. [PMID: 23692526] doi:10.1111/ijcp.12194
97. Chapple CR, Amarenco G, Lopez Aramburu MA, Everaert K, Liehne J, Lucas M, et al; BLOSSOM Investigator Group. A proof-of-concept study: mi-rabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013; 32: 1116-22. [PMID: 23424164] doi:10.1002/nau.22373
98. 3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012; 62:834-40. [PMID: 22695239] doi:10.1016/j.eururo.2012.05.053
99. Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013; 112:373-85. [PMID: 23826844] doi:10.1111/bju.12174
100. Dede H, Dolen I, Dede FS, Sivaslioglu AA. What is the success of drug treatment in urge urinary incontinence? What should be measured? Arch Gynecol Obstet. 2013; 287:511-8. [PMID: 23086134] doi:10.1007/s00404-012-2596-8
101. Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS, et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol. 2002; 9:247-52. [PMID: 12060436]
102. Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up. Int Urogynecol J. 2013; 24:1181-9. [PMID: 23160873] doi:10.1007/s00192-012-1992-8
103. Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010; 106:816-21. [PMID: 20151972] doi:10.1111/j.1464-410X2010.09202.x
104. Wein AJ, Khullar V, Wang JT, Guan Z. Achieving continence with anti-muscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int. 2007; 99:360-3. [PMID: 17155987]
105. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011; 28:151-60. [PMID: 21275440] doi:10.2165/11586740-000000000-00000
106. Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn. 2010; 29:551-4. [PMID: 19634167] doi:10.1002/nau.20787
107. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007; 52:1204-12. [PMID: 17651893]
108. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007; 178:2488-94. [PMID: 17937959]
109. Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004; 93:71-7. [PMID: 14678372]
110. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10:283-9. [PMID: 10543335]
111. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. 2001; 98:97-102. [PMID: 11516807]
112. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: a double-blind, placebo-controlled, multicentre clinical trial [Abstract]. Neurourol Urodyn. 2000; 19:488-90.
113. Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology. 2004; 64:269-74. [PMID: 15302476]
114. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 2009; 103:931-7. [PMID: 19281469] doi:10.1111/j.1464-410X.2009.08361.x
115. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol. 1998; 81:42-8. [PMID: 9467475]
116. Jonas U, Höfner K, Madersbacher H, Holmdahl TH; The International Study Group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol. 1997; 15:144-51. [PMID: 9144906]
117. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006; 67:275-80. [PMID: 16461077]
118. Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001; 24:703-13. [PMID: 11522122]
119. Chapple C. Fesoterodine: a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study [Abstract]. Presented at 2004 Congress of the International Continence Society, Paris, France, 25-27 August 2004. Abstract no. 142
120. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybu-tynin in the treatment of patients with overactive bladder. World J Urol. 2005; 23:248-52. [PMID: 16096831]
121. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, et al; Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007; 100:579-87. [PMID: 17669143]
122. Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, et al; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008; 102:1120-7. [PMID: 18990175] doi:10.1111/j.1464-410X.2008.07939.x
123. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al; YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93:303-10. [PMID: 14764127]
124. U.S. Food and Drug Administration. Drug approval package: Sanctura XR (trospium chloride) extended release capsules: medical review(s). 2007. Accessed at www.accessdata.fda.gov/drugsatfda-docs/nda/2007/022103s000-MedR.pdf on 31 July 2014.
125. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs. 2004; 13:1493-500. [PMID: 15500396]
126. U.S. Food and Drug Administration. Drug approval package: Enablex (darifenacin hydrobromide) extended release tablets: medical review(s). 2004. Accessed at www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21-513-Enablex.cfm on 31 July 2014.
127. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract. 2006; 60:119-26. [PMID: 16409440]
128. DuBeau CE, Khullar V, Versi E. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn. 2005; 24:13-20. [PMID: 15570576]
129. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001; 49: 700-5. [PMID: 11454106]
130. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al; Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001; 76:358-63. [PMID: 11322350]
131. Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39:1069-77. [PMID: 17333521]
132. Armstrong RB, Luber KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int Urol Nephrol. 2005; 37:247-52. [PMID: 16142551]
133. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxy-butynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003; 78:687-95. [PMID: 12934777]
134. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW; Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003; 62: 237-42. [PMID: 12893326]
135. Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004; 15:243-8. [PMID: 15517668]
136. Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, et al; STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007; 52:1195-203. [PMID: 17574730]
137. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract. 2008; 62: 1675-83. [PMID: 19143854] doi:10.1111/j.1742-1241.2008.01898.x
138. Solifenacin in a flexible dose regimen with tolterodine as an active comparator in a double-blind, double-dummy, randomized overactive bladder symptom trial (STAR). Proceedings of the 20th Congress of the European Association of Urology, Istanbul, Turkey, 16-20 March 2005.
139. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Brühl B, Hofner K, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003; 20:392-9. [PMID: 12811500]
140. Zellner M, Madersbacher H, Palmtag H, Stöhrer M, Bödeker RH; P195 Study Group. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Clin Ther. 2009; 31:2519-39. [PMID: 20109997] doi:10.1016/j.clinthera.2009.11.005
141. Bø K. Adherence to pelvic floor muscle exercise and long-term effect on stress urinary incontinence. A five-year follow-up study. Scand J Med Sci Sports. 1995; 5:36-9. [PMID: 7882126]
142. Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002; 288: 2293-9. [PMID: 12425706]
143. de Oliveira Camargo F, Rodrigues AM, Arruda RM, Ferreira Sartori MG, Girão MJ, Castro RA. Pelvic floor muscle training in female stress urinary incontinence: comparison between group training and individual treatment using PERFECT assessment scheme. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20: 1455-62. [PMID: 19690792] doi:10.1007/s00192-009-0971-1
144. Felićissimo MF, Carneiro MM, Saleme CS, Pinto RZ, da Fonseca AM, da Silva-Filho AL. Intensive supervised versus unsupervised pelvic floor muscle training for the treatment of stress urinary incontinence: a randomized comparative trial. Int Urogynecol J. 2010; 21:835-40. [PMID: 20179901] doi:10.1007/s00192-010-1125-1
145. Zanetti MR, Castro Rde A, Rotta AL, Santos PD, Sartori M, Girão MJ. Impact of supervised physiotherapeutic pelvic floor exercises for treating female stress urinary incontinence. Sao Paulo Med J. 2007; 125:265-9. [PMID: 18094892]
146. Konstantinidou E, Apostolidis A, Kondelidis N, Tsimtsiou Z, Hatzichristou D, Ioannides E. Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. Neurourol Urodyn. 2007; 26:486-91. [PMID: 17245777]
147. Ng SC, Lin TL, Chang SJ, Tai HL, Hu SW, Chen GD. Nursing intervention to enhance efficacy of home practice of pelvic floor muscle exercises in treating mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19:637-42. [PMID: 18004495]
148. Tsai YC, Liu CH. The effectiveness of pelvic floor exercises, digital vaginal palpation and interpersonal support on stress urinary incontinence: an experimental study. Int J Nurs Stud. 2009; 46:1181-6. [PMID: 19361800] doi: 10.1016/j.ijnurstu.2009.03.003
149. Berghmans LC, Frederiks CM, de Bie RA, Weil EH, Smeets LW, van Waalwijk van Doorn ES, et al. Efficacy of biofeedback, when included with pelvic floor muscle exercise treatment, for genuine stress incontinence. Neurourol Urodyn. 1996; 15:37-52. [PMID: 8696355]
150. Goode PS, Burgio KL, Locher JL, Roth DL, Umlauf MG, Richter HE, et al. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. JAMA. 2003; 290:345-52. [PMID: 12865375]
151. Glavind K, Nøhr SB, Walter S. Biofeedback and physiotherapy versus physiotherapy alone in the treatment of genuine stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 1996; 7:339-43. [PMID: 9203484]
152. Mørkved S, Bø K, Fjørtoft T. Effect of adding biofeedback to pelvic floor muscle training to treat urodynamic stress incontinence. Obstet Gynecol. 2002; 100:730-9. [PMID: 12383542]
153. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004; 63: 61-6. [PMID: 14751349]
154. Gameiro MO, Moreira EH, Gameiro FO, Moreno JC, Padovani CR, Amaro JL. Vaginal weight cone versus assisted pelvic floor muscle training in the treatment of female urinary incontinence. A prospective, single-blind, randomized trial. Int Urogynecol J. 2010; 21:395-9. [PMID: 20052573] doi:10.1007/s00192-009-1059-7
155. Seo JT, Yoon H, Kim YH. A randomized prospective study comparing new vaginal cone and FES-Biofeedback. Yonsei Med J. 2004; 45:879-84. [PMID: 15515199]
156. Elser DM, Wyman JF, McClish DK, Robinson D, Fantl JA, Bump RC; Continence Program for Women Research Group. The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence. Neurourol Urodyn. 1999; 18:427-36. [PMID: 10494113]
157. Wyman JF, Fantl JA, McClish DK, Bump RC; Continence Program for Women Research Group. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Am J Obstet Gynecol. 1998; 179: 999-1007. [PMID: 9790388]
158. Schagen van Leeuwen JH, Lange RR, Jonasson AF, Chen WJ, Viktrup L. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Maturitas. 2008; 60: 138-47. [PMID: 18547757] doi:10.1016/j.maturitas.2008.04.012
159. Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, et al; Duloxetine Dose Escalation Study Group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2007; 18:919-29. [PMID: 17160693]
160. van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, et al; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG. 2004; 111:249-57. [PMID: 14961887]
161. Duckett JR, Vella M, Kavalakuntla G, Basu M. Tolerability and efficacy of duloxetine in a nontrial situation. BJOG. 2007; 114:543-7. [PMID: 17355360]
162. Herschorn S. Current role of injectable agents for female stress urinary incontinence. Can J Urol. 2006; 13 Suppl 1:5-12. [PMID: 16526974]
163. Kim H, Suzuki T, Yoshida Y, Yoshida H. Effectiveness of multidimensional exercises for the treatment of stress urinary incontinence in elderly community-dwelling Japanese women: a randomized, controlled, crossover trial. J Am Geriatr Soc. 2007; 55:1932-9. [PMID: 17944890]